Text Size

Modeling Impaired Judgement in Cocaine Abusers - 6

This study has been completed.
Sponsor:
Collaborator:
New York MDRU
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00015236
First received: April 18, 2001
Last updated: November 3, 2005
Last verified: June 1998
History of Changes
  Purpose

The purpose of this study is for the modeling of impaired judgement in cocaine abusers.


Condition Intervention Phase
Cocaine-Related Disorders
Substance-Related Disorders
 Behavioral: Amantadine
 Phase 4

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Prevention
Official Title: Modeling Impaired Judgement in Cocaine Abusers

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Estimated Enrollment: 0
Study Start Date: March 1997
Detailed Description:

The objective of this study is to investigate recognition memory and appreciation of changing contingencies in relation to a response judgement.

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

(3 groups)Normal, healthy controls. Recent cocaine experience. Over 6 months since the last cocaine experience.

Exclusion Criteria:

Psychosis or mood disorder. History of seizure, head trauma

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00015236

Locations
United States, New York
New York MDRU
New York, New York, United States, 10010
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
New York MDRU
Investigators
Principal Investigator: John Rotrosen, M.D. New York MDRU
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00015236     History of Changes
Other Study ID Numbers: NIDA-5-0013-6, Y01-5-0013-6
Study First Received: April 18, 2001
Last Updated: November 3, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Amantadine
Antiparkinson Agents
Anti-Dyskinesia Agents
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Antiviral Agents
 Anti-Infective Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents

ClinicalTrials.gov processed this record on May 19, 2013